RT info:eu-repo/semantics/article
T1 Intravenous sildenafil for the treatment of persistent pulmonary hypertension of the newborn in a resource-limited setting
A1 Mesquita Ramírez, Mirta
A1 Samudio, Margarita
A1 Cardozo Sarubbi, Olivia Carolina
A1 Carrera Vargas, Dina Carmen
A1 Villalba Cabral, Pedro Luis
A2 Universidad Católica Nuestra Señora de la Asunción
AB Introduction: Treatment of severe persistent pulmonary hypertension of the newborn (PPHN) is based on the administration of selective pulmonary vasodilators. Inhaled nitric oxide is the only vasodilator therapy approved by the Food and Drug Administration. Non-selective vasodilator such as sildenafil has been the treatment available administered orally in most developing countries to manage newborn with PPHN. The aim of the study was to describe the effects and tolerability of intravenous (IV) sildenafil, as a loading dose of 0.4 mg/kg, followed by a continuous infusion of 1.6 mg/kg for 72 h on the oxygenation index (OI) in neonates with PPHN.Materials and Methods: This was an exploratory observational prospective study. Newborns ≥35 weeks of gestational age, post-natal age ≤72 h, with PPHN and an OI ≥20 were included in the study. Sildenafil was administered intravenously as a loading dose of 0.4 mg/kg, followed by a continuous infusion of 1.6 mg/kg for 72 h. During the sildenafil infusion, monitoring of vital signs and respiratory parameters was performed. The data were analysed with the SPSS v21.Results: Twenty-five infants were included. A significant improvement (P = 0.01) of OI (at admission, median: 25 and interquartile range [IQR] = 8) was observed at the end of the loading dose (3 h) (18 IQR = 4) and at 72 h (7 IQR = 4). No serious adverse effects were observed. Before hospital discharge, seven patients died.Conclusions: IV sildenafil administered, in newborns with PPHN with an IO ≥20, improved oxygenation in most of the patients without serious side effects.
PB Wolters Kluwer - Medknow Publications
SN 2249-4847
YR 2023
FD 2023-07-12
LK http://hdl.handle.net/20.500.14066/4507
UL http://hdl.handle.net/20.500.14066/4507
LA eng
NO Mesquita Ramírez, M. N., Samudio Acevedo, M., Cardozo Sarubbi, O. C., Carrera, D. C., & Villalba Cabral, P. L. (2023). Intravenous sildenafil for the treatment of persistent pulmonary hypertension of the newborn in a resource limited setting. Journal of Clinical Neonatology, 12(3), 99-104.https://doi.org/10.4103/jcn.jcn_33_23
NO Address for correspondence: Dr. Mirta Noemi Mesquita Ramirez, Department of Teaching and Research, General Pediatric Hospital Children of Acosta Ñu, Avenida Bacigalupo y de La Victoria, Reducto, San Lorenzo 111 475, Paraguay. E‑mail: mirtanmr@gmail.com
NO Consejo Nacional de Ciencia y Tecnología
DS MINDS@UW
RD 22-ene-2025